SLC35A2、前叶黄素亚基2在乳腺癌中的表达及其与临床观察指标和预后的关系

doi:10.3969/j.issn.1006-5725.2024.04.010

Abstract

Abstract:

Objective To investigate the expression of SLC35A2 and PFDN2 in breast cancer and their relationship with clinical indicators and prognosis. Methods TCGA database and TIMER 2.0 database were used to analyze the differences of SLC35A2 and PFDN2 expression in breast cancer tissues and paracancerous tissues； K?M database was used to create the survival curves of patients in the high and low expression groups of the two. qRT?PCR and immunohistochemistry were used to detect the expression of SLC35A2 and PFDN2 in the cancerous and paracancerous tissues， and the expression differences， the relationship between their expression levels and the clinical observation indexes were statistically analyzed， and the independent prognostic factors of breast cancer were screened out； K?M survival analysis was used to compare the prognostic differences between the groups and create the survival curves. Results The expression levels of SLC35A2 and PFDN2 in breast cancer tissues were significantly higher than those in paracancerous tissues according to the results of biopsy， qRT?PCR and immunohistochemistry， and the expression levels of SLC35A2 were significantly correlated with lymph node metastasis， while the expression of PFDN2 was significantly correlated with the diameter of the tumor and the metastasis of lymph nodes， and the expression of SLC35A2 and PFDN2 was an independent prognostic factor for breast cancer. patients had the worst prognosis. Conclusion The expression of SLC35A2 and PFDN2 in breast cancer tissues was closely related to clinical indicators and prognosis of breast cancer， and could be used as a potential target for breast cancer treatment.

Key words: breast cancer, SLC35A2, PFDN2, prognosis

CLC Number:

R737.9

Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis[J]. The Journal of Practical Medicine, 2024, 40(4): 496-502.

Figures/Tables 10

Tab.1

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

Tab.2

Tab.3

Tab.4

Fig.6

References 25

1	WILKINSON L， GATHANI T. Understanding breast cancer as a global health concern［J］. Br J Radiol， 2022，95（1130）：20211033. doi:10.1259/bjr.20211033 doi: 10.1259/bjr.20211033
2	SIEGEL R L， MILLER K D， WAGLE N S， et al. Cancer statistics， 2023［J］. CA Cancer J Clin， 2023，73（1）：17-48. doi:10.3322/caac.21763 doi: 10.3322/caac.21763
3	SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021，71（3）：209-249. doi:10.3322/caac.21660 doi: 10.3322/caac.21660
4	HUANG Z， HU C， LIU K， et al. Risk factors， prognostic factors， and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast： a population-based study［J］. BMC Cancer， 2020，20（1）：1145. doi:10.1186/s12885-020-07635-1 doi: 10.1186/s12885-020-07635-1
5	ZHAO H. The prognosis of invasive ductal carcinoma， lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast［J］. Breast Cancer， 2021，28（1）：187-195. doi:10.1007/s12282-020-01146-4 doi: 10.1007/s12282-020-01146-4
6	TRAYES K P， COKENAKES S. Breast Cancer Treatment［J］. Am Fam Physician， 2021，104（2）：171-178.
7	JACOBS A T， MARTINEZ CASTANEDA-CRUZ D， ROSE M M， et al. Targeted therapy for breast cancer： An overview of drug classes and outcomes［J］. Biochem Pharmacol， 2022，204：115209. doi:10.1016/j.bcp.2022.115209 doi: 10.1016/j.bcp.2022.115209
8	RODRIGUES-FERREIRA S， NAHMIAS C. Predictive biomarkers for personalized medicine in breast cancer［J］. Cancer Lett， 2022，545：215828. doi:10.1016/j.canlet.2022.215828 doi: 10.1016/j.canlet.2022.215828
9	HAYKAL M M， RODRIGUES-FERREIRA S， NAHMIAS C. Microtubule-Associated Protein ATIP3， an Emerging Target for Personalized Medicine in Breast Cancer［J］. Cells， 2021，10（5）：1080. doi:10.3390/cells10051080 doi: 10.3390/cells10051080
10	NAJJAR S， ALLISON K H. Updates on breast biomarkers［J］. Virchows Arch， 2022，480（1）：163-176. doi:10.1007/s00428-022-03267-x doi: 10.1007/s00428-022-03267-x
11	BARBA C， BLUMCKE I， WINAWER M R， et al. Clinical Features， Neuropathology， and Surgical Outcome in Patients With Refractory Epilepsy and Brain Somatic Variants in the SLC35A2 Gene［J］. Neurology， 2023，100（5）：e528-e542. doi:10.1212/wnl.0000000000201471 doi: 10.1212/wnl.0000000000201471
12	郭丽萍，张国淳，陈博，等. UGT1A1基因多态性与乳腺癌临床病理特征的相关性［J］. 实用医学杂志，2020，36（1）：1-5. doi:10.3969/j.issn.1006-5725.2020.01.001 doi: 10.3969/j.issn.1006-5725.2020.01.001
13	LIU C L， CHENG S P， HUANG W C， et al. Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer［J］. In Vivo， 2023，37（1）：262-269. doi:10.21873/invivo.13076 doi: 10.21873/invivo.13076
14	HE Q， DING Z， CHEN T， et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer［J］. Front Oncol， 2023，13：1164070. doi:10.3389/fonc.2023.1164070 doi: 10.3389/fonc.2023.1164070
15	VALS M A， ASHIKOV A， ILVES P， et al. Clinical， neuroradiological， and biochemical features of SLC35A2-CDG patients［J］. J Inherit Metab Dis， 2019，42（3）：553-564. doi:10.1002/jimd.12055 doi: 10.1002/jimd.12055
16	XU S， CHEN X， FANG J， et al. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2［J］. Front Immunol， 2023，14：1155182. doi:10.3389/fimmu.2023.1155182 doi: 10.3389/fimmu.2023.1155182
17	GIAMOUGIANNIS P， MARTIN-HIRSCH P L， MARTIN F L. The evolving role of MUC16 （CA125） in the transformation of ovarian cells and the progression of neoplasia［J］. Carcinogenesis， 2021，42（3）：327-343. doi:10.1093/carcin/bgab010 doi: 10.1093/carcin/bgab010
18	LUO G， JIN K， DENG S， et al. Roles of CA19-9 in pancreatic cancer： Biomarker， predictor and promoter［J］. Biochim Biophys Acta Rev Cancer， 2021，1875（2）：188409. doi:10.1016/j.bbcan.2020.188409 doi: 10.1016/j.bbcan.2020.188409
19	MATSUMOTO Y， JU T. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors［J］. Cancers （Basel）， 2023，15（14）：3536. doi:10.3390/cancers15143536 doi: 10.3390/cancers15143536
20	SCOTT D A， DRAKE R R. Glycosylation and its implications in breast cancer［J］. Expert Rev Proteomics， 2019，16（8）：665-680. doi:10.1080/14789450.2019.1645604 doi: 10.1080/14789450.2019.1645604
21	HADLEY B， LITFIN T， DAY C J， et al. Nucleotide Sugar Transporter SLC35 Family Structure and Function［J］. Comput Struct Biotechnol J， 2019，17：1123-1134. doi:10.1016/j.csbj.2019.08.002 doi: 10.1016/j.csbj.2019.08.002
22	莫绍剑. PFDN2在肝细胞癌中的表达及其临床意义［D］：太原：山西医科大学.
23	TAHMAZ I， SHAHMORADI GHAHE S， TOPF U. Prefoldin Function in Cellular Protein Homeostasis and Human Diseases［J］. Front Cell Dev Biol， 2021，9：816214. doi:10.3389/fcell.2021.816214 doi: 10.3389/fcell.2021.816214
24	MO S J， ZHAO H C， TIAN Y Z， et al. The Role of Prefoldin and Its Subunits in Tumors and Their Application Prospects in Nanomedicine［J］. Cancer Manag Res， 2020，12：8847-8856. doi:10.2147/cmar.s270237 doi: 10.2147/cmar.s270237
25	YESSEYEVA G， AIKEMU B， HONG H， et al. Prefoldin subunits （PFDN1-6） serve as poor prognostic markers in gastric cancer［J］. Biosci Rep， 2020，40（2）：BSR20192712. doi:10.1042/bsr20192712 doi: 10.1042/bsr20192712

基因	引物	上游	下游
SLC35A2	SLC35A2 引物序列	ATCCTCAGCATCCGCTACGC	CGAGCTTGAGCGTGTCCACA
	GAPDH 引物序列	GGAAGCTTGTCATCAATGGAAATC	TGATGACCCTTTTGGCTCCC
PFDN2	PFDN2 引物序列	TGTCCGCAGAGCAGGTGATT	AGCACCTCTTTGACAGTTCGC
	GAPDH引物序列	GGAAGCTTGTCATCAATGGAAATC	TGATGACCCTTTTGGCTCCC

组别	例数	SLC35A2		PFDN2
组别	例数	高表达	低表达	高表达	低表达
癌组织	80	50（62.5）	30（37.5）	46（57.5）	34（42.5）
癌旁组织	80	7（8.7）	73（91.3）	5（6.2）	75（93.8）
χ2值		50.39		48.383
P值		< 0.001		< 0.001

观察指标	SLC35A2				PFDN2
观察指标	高表达	低表达	χ2值	P值	高表达	低表达	χ2值	P值
年龄			0.164	0.685			2.970	0.085
≥ 55岁	24（64.9）	13（35.1）			17（45.9）	20（54.1）
< 55岁	26（60.5）	17（39.5）			28（65.1）	15（34.9）
肿瘤直径			1.105	0.293			7.798	0.005
≥ 2 cm	31（67.4）	15（32.6）			32（69.6）	14（30.4）
< 2 cm	19（55.9）	15（44.1）			13（38.2）	21（61.8）
淋巴结转移			4.063	0.044			10.219	0.001
有	19（79.2）	5（20.8）			20（83.3）	4（16.7）
无	31（44.6）	25（44.6）			25（44.6）	31（55.4）
组织学分级			0.272	0.602			0.288	0.591
Ⅰ-Ⅱ级	28（65.1）	15（34.9）			23（53.5）	20（46.5）
Ⅲ级	22（59.5）	15（40.5）			22（59.5）	15（40.5）
ER			0.380	0.538			0.033	0.857
阳	35（64.8）	19（35.2）			30（55.6）	24（44.4）
阴	15（57.7）	11（42.3）			15（57.7）	11（31.4）
PR			0.128	0.721			0.274	0.600
阳	32（64.0）	18（36.0）			27（54.0）	23（46.0）
阴	18（60.0）	12（40.0）			18（60.0）	12（40.0）
HER-2			1.204	0.273			0.763	0.382
阳	22（56.4）	17（43.6）			20（51.3）	19（48.7）
阴	28（68.3）	13（31.7）			25（61.0）	16（39.0）
Ki-67			0.302	0.583			0.150	0.699
≥ 20	32（60.4）	21（39.6）			29（54.7）	24（45.3）
< 20	18（66.7）	9（33.3）			16（59.3）	11（31.4）

观察指标	OS
	单因素分析		多因素分析
	HR（95%CI）	P值	HR（95%CI）	P值
年龄	0.702（0.291 ~ 1.695）	0.702	NA
肿瘤直径	2.127（0.825 ~ 5.487）	0.118	NA
淋巴结转移	1.092（0.440 ~ 2.708）	0.849	NA
组织学分级	1.430（0.592 ~ 3.453）	0.427	NA
ER	1.157（0.449 ~ 2.984）	0.762	NA
PR	0.881（0.365 ~ 2.126）	0.778	NA
HER-2	1.259（0.534 ~ 2.967）	0.598	NA
Ki-67	0.681（0.287 ~ 1.619）	0.385	NA
SLC35A2	4.878（1.434 ~ 16.594）	0.011	3.521（1.006 ~ 12.322）	0.049
PFDN2	4.404（1.479 ~ 13.115）	0.008	3.216（1.053 ~ 9.822）	0.040

[1]	Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.
[2]	Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267.
[3]	Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial （nonbiological） extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961.
[4]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[5]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[6]	Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin， interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475.
[7]	Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325.
[8]	Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329.
[9]	Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348.
[10]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[11]	Zhijie XIA,Jun LI,Qian GAO,Zhicheng LI,Zhongfang. XIA. Effect and prognosis of preauricular fistula treated by double⁃incision tunnel combined with preauricular tissue and cartilage resection [J]. The Journal of Practical Medicine, 2024, 40(22): 3179-3183.
[12]	Chengcai DAI,Zhenxing CHENG,Qianqian TU. The prognostic value of serum cystatin C combined with bedside renal ultrasound in patients with sepsis⁃induced acute kidney injury [J]. The Journal of Practical Medicine, 2024, 40(22): 3226-3231.
[13]	Kaiyang WANG,Jing TAO,Tingting WU,Jiahui YONG,Guoqing LI,Xiang XIE,Yining. YANG. Correlation of novel anthropometric indicators with long⁃term prognosis in patients with acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(21): 3040-3046.
[14]	Pixi WEI,Yu DENG,Cailing ZHAO,Liu XU,Min ZHANG. The expression of WDR5 in cervical cancer tissue and its relationship with clinical and pathological characteristics of patients [J]. The Journal of Practical Medicine, 2024, 40(2): 169-173.
[15]	Yinghua ZENG,Wenji LI,Li. ZHENG. The Impact of the timing of initial dressing change following PICC catheterization on postoperative breast cancer patients [J]. The Journal of Practical Medicine, 2024, 40(19): 2772-2777.

Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 25

Related Articles 15

Recommended Articles

Metrics

Comments